Fox Williams LLP acts for the London Technology Fund and Novartis on a further investment into Immune Targeting Systems (ITS) Limited

March 1, 2010

Fox Williams LLP acted for the London Technology Fund and Novartis Venture Fund, who were part of a consortium of investors which made a further investment of up to £8,650,000 into Immune Targeting Systems (ITS) Limited. 

Immune Targeting Systems (ITS) Limited is developing a universal synthetic flu vaccine. The funding will progress ITS’s lead candidate through to the completion of phase-II proof of concept efficacy studies.

The London Technology Fund is a specialist investor in new technology companies and is focused on the funding gap for new, high growth technology companies based in Greater London.

Paul Osborne, Doug Preece and Sean Williams of Fox Williams LLP advised The London Technology Fund and Novartis Venture Fund.

Related pages:

Corporate more

Technology, Media & Digital more

icons Addthis Print Contact Register


tel: +44 (0) 20 7628 2000
10 Finsbury Square, London, EC2A 1AF
View map


  • Top Ranked Chambers UK 2014 - Leading Firm
  • Ranked in Chambers Europe 2013 - Leading Individual
  • Ranked in Chambers Global 2014 - Leading Firm
  • Legal 500 - Leading Firm
  • The Lawyer UK 200 - Listed Firm
  • The Law Society Excellence Awards 2012 - Shortlisted
  • Investors in People - Bronze